文献速递慢性静脉疾病

美国单州与多州保险承运商静脉消融覆盖政策的差异与不一致性

Variations and inconsistencies in venous ablation coverage policies between single-state and multistate carriers in the United States.
PubMed 文献 · J Vasc Surg Venous Lymphat Disord · 2023-09-11

本研究比较美国单州承运商(SSC)与多州承运商(MSC)的静脉消融保险覆盖政策。共分析122项政策(SSC 85项,69.7%;MSC 37项,30.3%),发现大隐静脉消融尺寸标准差异显著,MSC更可能要求隐静脉反流时间>500 ms、覆盖机械化学消融,SSC更可能要求≥12周弹力袜治疗。结论指出政策存在差异,尤其尺寸标准不一致,需要循证指导制定更一致的政策。

要点

  • 共分析122项静脉消融覆盖政策,其中单州承运商85项(69.7%),多州承运商37项(30.3%)。
  • MSC较SSC更可能定义隐静脉反流时间>500 ms(81.1% vs 58.8%,P=0.04)。
  • SSC较MSC更可能要求≥12周弹力袜治疗(76.5% vs 48.7%,P=0.01)。

核心结论

  • 研究结果凸显静脉消融政策的差异,尤其是尺寸标准的显著不一致。
  • 与SSC相比,MSC更可能覆盖机械化学消融并要求更短的保守治疗时间。
  • 需要循证指导以制定更一致的静脉消融覆盖政策。

研究设计与样本

  • 研究审查美国静脉论坛静脉政策导航器中的各项政策,将政策分为单州承运商(SSC)和多州承运商(MSC)两组。
  • 比较两组政策的特征,包括特定静脉的解剖和血流动力学标准、保守治疗时长、疾病严重程度、症状及覆盖的手术类型。
  • 使用SAS 9.4版(SAS Institute Inc)进行统计分析。

主要发现

  • 共分析122项政策,分为SSC(n=85;69.7%)和MSC(n=37;30.3%)。
  • 大隐静脉消融尺寸要求存在显著差异:48%的政策未指定尺寸标准,其余政策规定最小尺寸范围为3至5.5 mm,但SSC与MSC之间无显著差异。
  • 小隐静脉和前副大隐静脉的发现类似。
  • MSC较SSC更可能定义隐静脉反流时间>500 ms(81.1% vs 58.8%;P=0.04)。
  • SSC与MSC在穿通静脉消融的尺寸和反流时间标准方面存在显著差异。

关键数值与推荐

  • 大隐静脉消融尺寸标准:48%的政策未指定尺寸标准,其余政策规定最小尺寸范围为3至5.5 mm。
  • 隐静脉反流时间>500 ms:MSC 81.1% vs SSC 58.8%(P=0.04)。
  • 机械化学消融覆盖:MSC 24.3% vs SSC 8.2%(P=0.03)。
  • ≥12周弹力袜治疗要求:SSC 76.5% vs MSC 48.7%(P=0.01)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Vein ablation is a common and effective treatment for patients with chronic venous insufficiency. The overuse of vein ablation despite the existence of evidence-based guidelines has resulted in insurance companies developing restrictive policies for coverage that create barriers to appropriate care. This study compares the insurance coverage by single-state carriers (SSCs) and multistate carriers (MSCs), highlighting the variations and inconsistencies in the various policies. METHODS: The American Venous Forum Venous Policy Navigator was reviewed for the various policies available in the United States. The policies were divided into SSCs and MSCs. The characteristics of the policies, including the anatomic and hemodynamic criteria for specific veins, duration of conservative treatment, disease severity, symptoms, and types of procedures covered, were compared between the two groups. SAS, version 9.4 (SAS Institute Inc) was used for statistical analysis. RESULTS: A total of 122 policies were analyzed and divided between SSCs (n = 85; 69.7%) and MSCs (n = 37; 30.3%). A significant variation was found in the size requirement for great saphenous vein ablation. Although 48% of the policies did not specify a size criterion, the remaining policies indicated a minimal size, ranging from 3 to 5.5 mm. However, no significant differences were found between SSCs and MSCs. Similar findings were encountered for the small and anterior accessory saphenous veins. MSCs were more likely to define a saphenous reflux time >500 ms compared with SSCs (81.1% vs 58.8%; P = .04). A significant difference was found between the SSCs and MSCs in the criteria for perforator ablation in terms of size and reflux time. MSCs were significantly more likely to provide coverage for mechanochemical ablation than were SSCs (24.3% vs 8.2%; P = .03). SSCs were more likely to require ≥12 weeks of compression stocking therapy than were MSCs (76.5% vs 48.7%; P = .01). No significant differences were found in the clinical indications between the two groups; however, MSCs were more likely to mention major hemorrhage than were SSCs. CONCLUSIONS: The results of this study highlight the variations in policies for venous ablation, in particular, the striking inconsistencies in size criteria. MSCs were more likely to cover mechanochemical ablation and require a shorter duration of conservative therapy before intervention compared with SSCs. Evidence-based guidance is needed to develop more coherent policies for venous ablation coverage.

来源:J Vasc Surg Venous Lymphat Disord,查看原文。版权归原作者所有。

引用

  1. Pinto P, Fukaya E, Rodriguez LE, et al. Variations and inconsistencies in venous ablation coverage policies between single-state and multistate carriers in the United States. J Vasc Surg Venous Lymphat Disord. 2023. PMID: 37703944. doi:10.1016/j.jvsv.2023.07.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。